- Home
- ANAB vs VTS Comparison
ANAB vs VTS Comparison
Compare ANAB & VTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- VTS
- Stock Information
- Founded
- ANAB 2005
- VTS 2014
- Country
- ANAB United States
- VTS United States
- Employees
- ANAB N/A
- VTS N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- VTS Oil & Gas Production
- Sector
- ANAB Health Care
- VTS Energy
- Exchange
- ANAB Nasdaq
- VTS Nasdaq
- Market Cap
- ANAB 759.5M
- VTS 724.6M
- IPO Year
- ANAB 2017
- VTS N/A
- Fundamental
- Price
- ANAB $20.55
- VTS $21.10
- Analyst Decision
- ANAB Buy
- VTS Strong Buy
- Analyst Count
- ANAB 10
- VTS 4
- Target Price
- ANAB $36.38
- VTS $30.25
- AVG Volume (30 Days)
- ANAB 1.0M
- VTS 411.8K
- Earning Date
- ANAB 05-08-2025
- VTS 05-05-2025
- Dividend Yield
- ANAB N/A
- VTS 10.92%
- EPS Growth
- ANAB N/A
- VTS N/A
- EPS
- ANAB N/A
- VTS 0.64
- Revenue
- ANAB $91,280,000.00
- VTS $220,498,000.00
- Revenue This Year
- ANAB N/A
- VTS $36.97
- Revenue Next Year
- ANAB $37.76
- VTS $4.55
- P/E Ratio
- ANAB N/A
- VTS $32.97
- Revenue Growth
- ANAB 432.03
- VTS 3.87
- 52 Week Low
- ANAB $12.21
- VTS $18.90
- 52 Week High
- ANAB $41.31
- VTS $28.41
- Technical
- Relative Strength Index (RSI)
- ANAB 65.12
- VTS 41.68
- Support Level
- ANAB $15.40
- VTS $18.90
- Resistance Level
- ANAB $19.82
- VTS $20.92
- Average True Range (ATR)
- ANAB 1.49
- VTS 1.22
- MACD
- ANAB 0.16
- VTS -0.14
- Stochastic Oscillator
- ANAB 96.26
- VTS 35.02
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About VTS Vitesse Energy Inc.
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.